FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org November 4, 2007 (10.1056/NEJMe0706859)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In Greek mythology, Scylla was a ferocious beast and Charybdis was a monstrous whirlpool. The wily Odysseus successfully navigated between these two dangers by steering closer to Scylla, though he did lose a few crew members to her. In a similar manner, the astute clinician managing myocardial ischemia by using antiplatelet therapy attempts to balance coronary thrombosis, the basic cause of myocardial ischemia, against hemorrhage, the most-feared complication of antiplatelet therapy. There are many pathways by which antiplatelet drugs may antagonize platelet activation or aggregation, all of which increase the risk of bleeding, and many of which decrease the risk . . . [Full Text of this Article]

Source Information

From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland.

This article (10.1056/NEJMe0706859) was published at www.nejm.org on November 4, 2007. It will appear in the November 15 issue of the Journal.

This article has been cited by other articles:

• Serebruany, V., Pasceri, V., Patti, G., Di Sciascio, G., von Lewinski, F., Riggert, J., Paulus, W., Wiviott, S. D., Braunwald, E., Antman, E. M., Bhatt, D. L. (2008). Prasugrel versus clopidogrel.. NEJM 358: 1298-1299 [Full Text]  
• (2007). Prasugrel in Patients with Acute Coronary Syndromes. JWatch Oncology and Hematology 2007: 1-1 [Full Text]